Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity

Inclusion Criteria: * Non-resectable pancreatic cancer * Biopsy proven adenocarcinoma compatible with pancreatic origin (primary tumor or metastasis) * If only biopsy from metastasis can be obtained, the patient must have a previously resected or image proven tumor of the pancreas * Deemed non-resectable at a multidisciplinary conference * Candidate to standard systemic therapy, defined as one of * Gemcitabine monotherapy, * Gemcitabine and nab-paclitaxel combination, * Gemcitabine and capecitabine combination, * 5-fluorouracil, oxaliplatin and irinotecan combination (FOLFIRINOX), or * New standard treatments approved by the multidisciplinary cancer group 'Danish Pancreatic Cancer Group' in the inclusion period. * Measurable disease according to RECIST 1.1 * ECOG performance status 0-2 * Age at least 18 years * Adequate bone marrow, liver and renal function allowing systemic chemotherapy * Absolute neutrophil count ≥1.5x10\^9/l and thrombocytes ≥ 100x10\^9/l * Bilirubin ≤ 3 x upper normal value and alanine aminotransferase ≤ 5 x upper normal value * Calculated or measured renal glomerular filtration rate at least 30 mL/min * Contraception for fertile women and for male patients with a fertile partner. Intrauterine device, vasectomy of a female subject's male partner or hormonal contraceptive are acceptable * Written and orally informed consent Exclusion Criteria: * Potentially resectable disease * Incapacity, frailty, disability, or comorbidity to a degree that according to the investigator is not compatible with participation in the protocol * Other active malignant disease requiring therapy * Other systemic anti-cancer therapy (palliative radiotherapy is allowed) * Pregnant (positive pregnancy test) or breast feeding women